http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2015105329-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2013-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2015105329-A |
| titleOfInvention | CD95 SIGNAL WAY INHIBITORS FOR MDS TREATMENT |
| abstract | 1. A CD95 signaling pathway inhibitor for use in the treatment of myelodysplastic syndrome (MDS), where MDS is selected from the low-risk MDS subgroup according to IPSS and / or the MDS subgroup with intermediate-1 risk (int-1) and where the inhibitor binds the CD95 receptor ( CD95) and / or CD95 ligand (CD95L) .2. A CD95 signaling pathway inhibitor for use according to claim 1, wherein the inhibitor is a compound that improves the growth of erythroid precursors. A CD95 signaling pathway inhibitor for use according to claim 1, wherein the inhibitor is an antibody, in particular an antibody or fragment thereof that binds CD95L. A CD95 signaling pathway inhibitor for use according to claim 2, wherein the inhibitor is an antibody, in particular an antibody or fragment thereof that binds CD95L. A CD95 signaling pathway inhibitor for use according to claim 1, wherein the inhibitor is a CD95 receptor molecule or part thereof that binds a CD95 ligand and / or a CD95 ligand inhibitor. A CD95 signaling pathway inhibitor for use according to claim 2, wherein the inhibitor is a CD95 receptor molecule or part thereof that binds an SB95 ligand and / or a CD95 ligand inhibitor. A CD95 signaling pathway inhibitor for use according to claim 1, wherein the inhibitor is a chimeric protein that binds to CD95L. A CD95 signaling pathway inhibitor for use according to claim 2, wherein the inhibitor is a chimeric protein that binds CD95L. A CD95 signaling pathway inhibitor for use according to claim 7, wherein the chimeric protein comprises an extracellular domain of CD95 or a functional fragment thereof and a human Fc domain or functional fragment thereof. A CD95 signaling pathway inhibitor for use according to claim 8, wherein the chimeric protein comprises an extracellular domain of CD95 or a functional fragment thereof and a human Fc domain or functional fragment thereof. CD95 signaling pathway inhibitor for use according to claim 9, wherein |
| priorityDate | 2012-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414859283 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6547 |
Total number of triples: 26.